Characterization of the male ApcMin/+ mouse as a hypogonadism model related to cancer cachexia
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Summary: Cancer cachexia, the unintentional loss of lean body mass, is associated with decreased quality of life and poor patient survival. Hypogonadism, involving a reduction in circulating testosterone, is associated with the cachectic condition. At this time there is a very limited understanding of the role of hypogonadism in cancer cachexia progression. This gap in our knowledge is related to a lack of functional hypogonadal models associated with cancer cachexia. The ApcMin/+ mouse is an established colorectal cancer model that develops an IL-6 dependent cachexia which is physiologically related to human disease due to the gradual progression of tumor development and cachexia. The purpose of this study was to assess the utility of the ApcMin/+ mouse for the examination of hypogonadism during cancer cachexia and to investigate if IL-6 has a role in this process. We report that ApcMin/+ mice that are weight stable have comparable testosterone levels and gonad size compared to wild type mice. Cachectic ApcMin/+ mice exhibit a reduction in circulating testosterone and gonad size, which has a significant association with the degree of muscle mass and functional strength loss. Circulating testosterone levels were also significantly associated with the suppression of myofibrillar protein synthesis. Skeletal muscle and testes androgen receptor expression were decreased with severe cachexia. Although testes STAT3 phosphorylation increased with severe cachexia, systemic IL-6 over-expression for 2 weeks was not sufficient to reduce either testes weight or circulating testosterone. Inhibition of systemic IL-6 signaling by an IL-6 receptor antibody to ApcMin/+ mice that had already initiated weight loss was sufficient to attenuate a reduction in testes size and circulating testosterone. In summary, the ApcMin/+ mouse becomes hypogonadal with the progression of cachexia severity and elevated circulating IL-6 levels may have a role in the development of hypogonadism during cancer cachexia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 1×
“We next treated Apc mice exhibiting initial body weight loss with an IL-6 receptor antibody for two weeks to block systemic IL-6 signaling including both classical and trans IL-6 signaling (Rose-John, 2012), during a pivotal time point in the progression of cachexia.”
MethodTestosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · cited 1×
“, 1996) or without (Katznelson et al., 1996; Mauras et al., 1998) an underlying disease.”
BackgroundFrequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631
Mitochondrial fission and remodelling contributes to muscle atrophy
Romanello, V., Guadagnin, E., Gomes, L., Roder, I., Sandri, C., Petersen, Y., Milan, G., Masiero, E., Del Piccolo, P., Foretz, M., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.60 · Cited by 596 · cited 1×
“Recent evidence supports the regulatory interaction between mitochondrial function and protein turnover (Romanello et al., 2010).”
BackgroundBhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Mac, R. P., Lee, M., Yarasheski, K. E., Sinha-Hikim, I., Dzekov, C., Dzekov, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1184 · Cited by 544
Sex hormones, inflammation and the metabolic syndrome: a population-based study
Laaksonen, D., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T., Salonen, R., Rauramaa, R., & Salonen, J. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490601 · Cited by 438
White, J. P., Baynes, J. W., Welle, S. L., Kostek, M. C., Matesic, L. E., Sato, S., & Carson, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024650 · Cited by 260
Self-citationKadi, F. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.118 · Cited by 200
Simon, D., Charles, M.-A., Lahlou, N., Nahoul, K., Oppert, J.-M., Gouault-Heilmann, M., Lemort, N., Thibult, N., Joubert, E., Balkau, B., et al. (2001) · Diabetes Care · doi:10.2337/diacare.24.12.2149 · Cited by 136
Decreased intestinal polyp multiplicity is related to exercise mode and gender in ApcMin/+ mice
Mehl, K. A., Davis, J. M., Clements, J. M., Berger, F. G., Pena, M. M., & Carson, J. A. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00975.2004 · Cited by 99 · cited 1×
“Despite polyp formation early in adulthood, (Mehl et al., 2005) testosterone levels in the Apc mouse are maintained until the later stages of cachexia, which is similar to human cachexia.”
BackgroundSelf-citation
Cited by
Cachexia: A systemic consequence of progressive, unresolved disease
Ferrer, M., Anthony, T. G., Ayres, J. S., Biffi, G., Brown, J. C., Caan, B. J., Cespedes Feliciano, E. M., Coll, A. P., Dunne, R. F., Goncalves, M. D., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.028 · Cited by 260
Muscle metabolism and atrophy: let’s talk about sex
Rosa-Caldwell, M. E., & Greene, N. P. (2019) · Biology of Sex Differences · doi:10.1186/s13293-019-0257-3 · Cited by 202
“Hypogonadism also commonly accompanies cancer cachexia [117, 118], and recent works have begun to evaluate the sufficiency of drugs with androgen-like binding and testosterone itself as pharmacological agents for the treatment of cancer cachexia in men [123, 124].”
BackgroundAndrogen-mediated regulation of skeletal muscle protein balance
Rossetti, M. L., Steiner, J. L., & Gordon, B. S. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.031 · Cited by 95
“Consistent with this change, the phosprylation of FoxO3a (Ser253) was decreased in the gastrocnemius of castrated mice providing further support for this transcription factor in the atrogene expression during hypogonadism (White et al., 2013).”
BackgroundResultInfluentialRossetti, M. L., Esser, K. A., Lee, C., Tomko, R. J., Eroshkin, A. M., & Gordon, B. S. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00177.2019 · Cited by 37
Rossetti, M. L., Steiner, J. L., & Gordon, B. S. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.01.017 · Cited by 24
Metadata
- Authors
- White, J. P., Puppa, M. J., Narsale, A., & Carson, J. A.
- Venue
- Biology Open
- Publisher
- The Company of Biologists
- Published
- 2013-11-04
- Volume
- 2
- Issue
- 12
- Pages
- 1346-1353
- ISSN
- 2046-6390 (ISSN-L)
- OpenAlex
- W2135214326
- Cited by
- 47
- References
- 11
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.